Evidence map›Paper›PMID 24892144›Full record

Trial reportThe Journal of allergy and clinical immunology2014

Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications.

Judie A Howrylak, Anne L Fuhlbrigge, Robert C Strunk, Robert S Zeiger, Scott T Weiss, Benjamin A Raby, Childhood Asthma Management Program Research Group

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 132 citations in OpenAlex.

  1. Treatment by biomarker-informed endotype vs guideline care in children with difficult-to-treat asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022
    Trial
  2. Features of asthma which provide meaningful insights for understanding the disease heterogeneity.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2018
    Trial
  3. Context-specific genetic effects inform endotypes and treatment in asthma.The Journal of allergy and clinical immunology · 2026
    Article
  4. MicroRNA clustering in pediatric asthma reveals differential corticosteroid responsiveness.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pediatric asthma population risk stratification using k-means clustering.The Journal of asthma : official journal of the Association for the Care of Asthma · 2025
    Article
  10. Review
  11. Article
  12. Asthma Phenotypes and Biomarkers.Respiratory care · 2025
    Review
  13. C3G and Ig-MPGN-treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  14. Review
  15. Article
  16. Kidney diseases.Immunological reviews · 2023
    Review
  17. Article
  18. Asthma clustering methods: a literature-informed application to the children's health study data.The Journal of asthma : official journal of the Association for the Care of Asthma · 2022
    Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Judie A Howrylak
Anne L Fuhlbrigge
Robert C Strunk
Robert S Zeiger
Scott T Weiss
Benjamin A Raby
Childhood Asthma Management Program Research Group
Brigham and Women's Hospital · USKaiser Permanente · USPenn State Milton S. Hershey Medical Center · USSt. Louis Children's Hospital · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI POLONSKY, KENNETH S · 1985 to 2007
$25.4M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
The Genetic Epidemiology of Asthma in Costa RicaR37HL066289 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 2007 to 2015
$14.6M
The Asthma BioRepository for Integrative Genomics ResearchRC2HL101543 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RABY, BENJAMIN ALEXANDER, WEISS, SCOTT T · 2009 to 2010
$8.3M
Genetics and Gene Expression Profiling in AsthmaR01HL086601 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RABY, BENJAMIN ALEXANDER · 2007 to 2015
$6.8M
The Integrative Genomics of Acute Asthma ControlR01HL118455 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MILLSTEIN, JOSHUA, RABY, BENJAMIN ALEXANDER · 2014 to 2024
$6.5M
Structural Genetic Variation in AsthmaR01HL093076 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RABY, BENJAMIN ALEXANDER · 2008 to 2011
$3.5M
CLINICAL CENTER FOR CAMPN01HR016049 · HR · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 1991 to 2000
$1.0M
CLINICAL COORDINATING CENTER FOR CAMPN01HR016044 · HR · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 1991 to 2006
$729k
NCATS NIH HHS UL1 TR001082NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000051NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR0099718-24NCRR NIH HHS M01RR02719-14NCRR NIH HHS RR00036NHLBI NIH HHS N01 HR016044NHLBI NIH HHS N01 HR016045NHLBI NIH HHS N01 HR016046NHLBI NIH HHS N01 HR016047NHLBI NIH HHS N01 HR016048NHLBI NIH HHS N01 HR016049NHLBI NIH HHS N01 HR016050NHLBI NIH HHS N01 HR016051NHLBI NIH HHS N01 HR016052NHLBI NIH HHS N01-HR-16044NHLBI NIH HHS N01-HR-16045NHLBI NIH HHS N01-HR-16046NHLBI NIH HHS N01-HR-16047NHLBI NIH HHS N01-HR-16048NHLBI NIH HHS N01-HR-16049NHLBI NIH HHS N01-HR-16050NHLBI NIH HHS N01-HR-16051NHLBI NIH HHS N01-HR-16052NHLBI NIH HHS R01 HL086601NHLBI NIH HHS R01 HL093076NHLBI NIH HHS R01 HL118455NHLBI NIH HHS R37 HL066289NHLBI NIH HHS RC2 HL101543NHLBI NIH HHS RC2-HL101543NHLBI NIH HHS U01 HL065899PHS HHS R01-086601PHS HHS R01-093076
6 · The paper itself

Abstract

backgroundAlthough recent studies have identified the presence of phenotypic clusters in asthmatic patients, the clinical significance and temporal stability of these clusters have not been explored.

objectiveOur aim was to examine the clinical relevance and temporal stability of phenotypic clusters in children with asthma.

methodsWe applied spectral clustering to clinical data from 1041 children with asthma participating in the Childhood Asthma Management Program. Posttreatment randomization follow-up data collected over 48 months were used to determine the effect of these clusters on pulmonary function and treatment response to inhaled anti-inflammatory medication.

resultsWe found 5 reproducible patient clusters that could be differentiated on the basis of 3 groups of features: atopic burden, degree of airway obstruction, and history of exacerbation. Cluster grouping predicted long-term asthma control, as measured by the need for oral prednisone (P < .0001) or additional controller medications (P = .001), as well as longitudinal differences in pulmonary function (P < .0001). We also found that the 2 clusters with the highest rates of exacerbation had different responses to inhaled corticosteroids when compared with the other clusters. One cluster demonstrated a positive response to both budesonide (P = .02) and nedocromil (P = .01) compared with placebo, whereas the other cluster demonstrated minimal responses to both budesonide (P = .12) and nedocromil (P = .56) compared with placebo.

conclusionPhenotypic clustering can be used to identify longitudinally consistent and clinically relevant patient subgroups, with implications for targeted therapeutic strategies and clinical trials design.

Indexed as

AsthmaPhenotypeAdministration, InhalationAnti-Inflammatory AgentsBudesonideChildChild, PreschoolCluster AnalysisFemaleFollow-Up StudiesHumansMaleNedocromilPrednisoloneAnti-Inflammatory AgentsBudesonideNedocromilPrednisolone

Identifiers

PMID24892144
PMCPMC4047642
OpenAlexW2003253816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.